1.Preparation and In Vitro Permeability Study of Dihydroartemisinin Ointment
Feng DU ; Rongsheng LI ; Naijie WANG
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(09):-
Objective To optimize the formulation of Dihydroartemisinin ointment and study its characteristics of penetration enhancers.Method A method of transdermal experiment in vitro was established for DHA.The penetration rate in vitro was examined by HPLC,and coincided the DHA cumulative permeation curve with the Higuchi equation.Result The penetration rate of DHA from DHA ointment made up of water-soluble carbopol and Azone was the highest in all formulations,up to 27.262 ?g/(h?cm2).The cumulative permeation curve which coincided with the Higuchi equation was better.Conclusion The formulation which made up of water-soluble carbopol and Azone was optimized.
2.Matrix effect on the determination of Potency in Recombinant Coagulation Factor Ⅷ for injection
Jialin CHU ; Yaling DING ; Wenhu HUANG ; Jiajun WU ; Xiao JIANG ; Yang GAO ; Xun LIU ; Shenghua DU ; Yizhou XIE
Chinese Journal of Blood Transfusion 2022;35(12):1262-1265
【Objective】 To investigate the matrix effect on the determination of potency in Recombinant Human Coagulation Factor Ⅷ for Injection (rFⅧ). 【Methods】 Two different detection matrices were used to establish two methods for detecting the potency in Recombinant Human Coagulation Factor Ⅷ for Injection. And the matrix effect on the determination of potency was determined, including specificity, linearity, repeatability, accuracy and intermediate precision. 【Results】 As to the specificity, the recoveries of the two substrates at high vs low concentration level were 112% and 110% vs 104% and 109%, respectively. As to the linearity, in the range of (0.125-1.000) IU/mL, the correlation coefficient between concentration and coagulation time of standard/ sample was higher than 0.99. As to the accuracy/repeatability, the recoveries of two matrices was 104% and 102%, and RSD was 2.4% and 1.9%. As to the intermediate precision, personnel factor of two matrices was 0.72 and 0.23, date factor was 0.79 and 0.85, and RSD(for 12 times) was 4.2% and 3.0%. Comparison of two matrices was as follows: Deviation in test results of 6 batches of rFⅧ was all lower than 5%. There was no significant difference between two matrices. 【Conclusion】 The two matrices for potency detection show good performance including specificity, linearity, repeatability, accuracy, and intermediate precision. They are suitable for the determination of potency in rFⅧ products.
3.THE USE OF 6-AMINOCAPROIC ACID (EACA) TO REDUCE POSTOPERATIVE BLEEDING FOLLOWING IN MITRAL VALVE REPLACEMENT
Zhenglong DU ; Zhusheng KUANG ; Rongsheng XIONG ; Zhigang WANG ; Yibo LIU ; Hongtao XIA ; Tao BAI ; Sheng DENG ; Fu ZHANG
Chinese Journal of Postgraduates of Medicine 2001;24(5):20-21
Objective To determine the effect of 6-aminocaproic acid (EACA) to reduce postoperation bleeding following in mitral valve replacement.Method 50 adult patients uddergoing mitral valve replacement was adopted a double-bisind randomized trial to be divided into two groups.Each group is 25 patients.The patients in control groups received NS,the ones in study groups received NS as same as control groups but added EACE 10 g by intravation.The bleeding amount in cavitas thoracis were recorded on the sixth,twenty-fourth postoperative hours and ACT was recorded as well.Results The bleeding amount in study groups on the sixth postoperative hours were (290.0±41.3) ml.On twenty-fourth postoperative hours were (336.3±81.3) ml.The bleeding amount in control groups on the sixth postoperative hours were (393.4±73.6) ml.On twenty-fourth postoperative hours were (450.0±79.6) ml.The bleeding amount in study groups were decreased significantly as compared with in control groups (P<0.05).Conclusion:6-aminocaproic acid can reduce postoperation bleeding following in mitral valve replacement.
4.Interpretation of Local Standard Specification for Pharmacy Intravenous Centralized Admixture in Beijing
Yawei DU ; Ning PANG ; Yu BI ; Rongsheng ZHAO
China Pharmacy 2021;32(1):12-16
OBJECTIVE:To interpret the key points in local standard Specification for Pharmacy Intravenous Centralized Admixture(DB11/T 1701-2019)(Beijing Local Standard for short )in Beijing ,and to provide guidance and reference for managers of medical institutions and staff of PIVAS to deeply understand the standard and further improve the quality of PIVAS in medical institutions. METHODS :The background and main content of Beijing Local Standard were interpreted in detail ,and then compared with Quality Specification of Pharmacy Intravenous Admixture (National Specification for short )promulgated by Chinese National Ministry of Public Health and Quality Specification of Pharmacy Intravenous Admixture Services of Guangdong Provincial (Trial)(Specification of Guangdong Province for short )promulgated by Guangdong Pharmaceutical Association. RESULTS & CONCLUSIONS:Beijing Local Standard had been promulgated and implemented by Beijing Municipal Administration for Market Regulation on April 1st,2020. The text of Beijing Local Standard is divided into 7 parts,mainly including the scope of application,normative references ,terms and definitions ,basic requirement ,environmental requirements (design,location, layout),equipment and facilities (ventilation system and console ,operation and maintenance ),and admixture requirements. Beijing Local Standard further refines the relevant contents on the basis of following the requirements of National Specification . Like Specification of Guangdong Province ,the applicability and operability of the standard are enhanced by combining their local characteristics and practice status. As the first local standard in this domain ,the local standard is expected to promote the improvement of the working quality of PIVAS in Beijing ,enable the PIVAS of proposed construction ,under construction and operation maintenance to meet uniform standards and reduce the failure of acceptance or reconstruction after completion.
5.Effects of rehabilitation exercise on exercise tolerance and cardiovascular risk factors in patients with non-acute coronary syndrome after interventional therapy: A randomized controlled trial
Dan HUANG ; Rongsheng DU ; Hongwei ZHANG ; Muying QU ; Guiying YOU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2021;28(08):915-920
Objective To investigate the effects of rehabilitation exercise on exercise tolerance and cardiovascular risk factors in patients with non-acute coronary syndrome (non-ACS) after interventional therapy. Methods A total of 102 patients with coronary heart disease and non-ACS in our hospital from December 2018 to June 2019 were selected and randomly divided into a control group (n=51, 30 males and 21 females with an average age of 56.1±4.8 years) and a trial group (n=51, 34 males and 17 females with an average age of 55.1±4.9 years). The control group received routine treatment, while the trial group received regular supervised rehabilitation exercise on the basis of routine treatment. Patients were followed up for 6 months to compare the differences in cardiovascular risk factors (blood pressure, blood lipid, fasting blood glucose), 6-minute walking distance (6MWD), adverse lifestyle changes and treatment compliance between the two groups after treatment. Results The difference of 6MWD between the two groups was statistically significant (P<0.05). In the trial group, 6MWD increased after intervention compared with that before intervention, and the difference was statistically significant (P<0.05). Comparison of total cholesterol (TC), high density liptein cholesterol (HDL-C), low density liptein cholesterol (LDL-C) and fasting blood glucose in the trial group before and after intervention showed statistically significant differences (P<0.05). The differences in TC, HDL-C and LDL-C in the control group before and after intervention were statistically significant (P<0.05). It was statistically significant in dietary compliance rate, smoking cessation rate and alcohol cessation rate between the two groups (P<0.05); the differences in the dietary compliance and drug compliance of the trial group before and after intervention were statistically significant (P<0.05). Conclusion Regular supervised rehabilitation exercise can significantly improve the exercise tolerance and cardiovascular risk factors of non-ACS patients after coronary intervention treatment, so as to improve the quality of life and long-term prognosis of non-ACS patients, which is worthy of clinical application.
6.Analysis of the real situation of medication in the population with gout achieving T2T indicators: a multicentre real-world study
Weiqin GAO ; Xuezhong GONG ; Yuanyuan ZHANG ; Xingchen DU ; Ping JIANG ; Fengyuan GUAN ; Ying LU ; Xiao SU ; Hongze JIANG ; Hongbin LI ; Yongfei FANG ; Hengli ZHAO ; Jiangyun PENG ; Mingli GAO ; Li SU ; Fang HE ; Qingwen TAO ; Chunrong HU ; Peng LI ; Zeguang LI ; Yuelan ZHU ; Ying GU ; Ming ZHANG ; Rongsheng WANG ; Ting JIANG ; Xiaolin YANG ; Qi ZHU ; Quan JIANG ; Jianyong ZHANG ; Xiaolei FAN ; Yu XUE ; Dongyi HE
Chinese Journal of Rheumatology 2023;27(6):361-367
Objective:To explore the therapeutic characteristics of population with gout achieving treat-to-target (T2T) indicators through real-world research and evaluate their safety.Methods:A total of 3 287 patients diagnosed with gout by rheumatologists in 21 first-class tertiary hospitals in 10 provinces, municipalities, and autonomous regions in China from January 2015 to December 2021 were included in this polycentric cross-sectional study. The database included patients′ general information, disease characteristics, and clinical application of traditional Chinese and Western medicine treatment measures. SPSS and Excel software were used for data analysis. Frequency analysis, cluster analysis, and factor analysis were used to summarize the characteristics and rules of treatment measures for patients with gout who achieved the target after treatment. The occurrence of adverse events (AE) was recorded during treatment.Results:After treatment, 691 visits (7%) achieved the serum urate (SUA) target, and the most frequent use of urate-lowering therapy (ULT) was febuxostat, followed by benzbromarone. The most common treatment options were following: GroupⅠ: traditional Chinese medicine (TCM) decoction-TCM external treatment-physical exercise-proprietary Chinese medicine; GroupⅡ: ferulic acid-nonsteroidal anti-inflammatory drugs (NSAIDs); Group Ⅲ: allopurinol-sodium bicarbonate-benzbromarone; Group Ⅳ: glucocorticoid-colchicine; Group Ⅴ: febuxostat. A total of 5 898 visits (60%) chieved manifestations of joint pain VAS scores target, and the most frequently used drug to control joint symptoms was NSAIDs. The frequency of use of drugs to control joint symptoms were 2 118 times (usage rate reached 35.9%), while the frequency of ULT were 2 504 times (usage rate reached 42.5%), which was higher than the joint symptom control drug. The most common treatment options were following: Group Ⅰ: proprietary Chinese medicine-TCM decoction-TCM external treatment-physical exercise; Group Ⅱ: NSAIDs-colchicine hormones; Group Ⅲ: allopurinol, Group Ⅳ: benzbromarone; Group Ⅴ: febuxostat. A total of 59 adverse events occurred during treatment.Conclusion:The proportions of gout patients who reach target serum urate level & good control of joint symptoms are both very low, and ULT and anti-inflammatory prescription patterns are very different from international guidelines, so it is necessary to strengthen the standardized management of gout patients. At the same time, life intervention measures account for a certain proportion of the treatment plans for the T2T population, and further exploration is needed.
7.Interpretation for Evidence-based Practice Guideline of Medication Therapy of High-dose Methotrexate in China
Zaiwei SONG ; Shuang LIU ; Rongsheng ZHAO ; Suodi ZHAI ; Xianglin ZHANG ; Youping LI ; Guanhua DU ; Yuankai SHI ; Liyan MIAO ; Lingli ZHANG ; Hongmei JING
China Pharmacy 2022;33(16):2032-2039
Evidence-based Practice Guideline of Medication Therapy of High-dose Methotrexate in China was published in the British Journal of Clinical Pharmacology in February 2022. The guideline followed the latest definition of clinical practice guideline and the methodology specification for the guideline development of WHO. The Grading of Recommendations Assessment , Development,and Evaluation (GRADE)approach was applied to rate the quality of evidence and determine the strength of recommendations. Finally ,this guideline presents 28 recommendations covering the whole process of clinical medication of high-dose methotrexate ,involving evaluation prior to administration (liver and renal function ,pleural effusion and ascites , comedication,genetic testing ),pre-treatment and routine dosing regimen (pretreatment of hydration and alkalization ,urine alkalization,routine dosing regimen ),therapeutic drug monitoring (necessity,method,timing,target concentration ),leucovorin rescue(rescue timing ,rescue regimen ,rescue dose optimization ),and management of toxicities (liver and kidney function monitoring,supportive treatment ,blood purification treatment ). This article aims to summarize and interpret the recommendations of this guideline ,so as to promote the better promotion and implementation of this guideline and provide comprehensive technical support and suggestions for whole-course individualized administration of high-dose methotrexate in China.
8.Construction of Integrated Emergency Management Model for Novel Coronavirus Pneumonia Epidemic Prevention and Control in Hospital Pharmacy Department
Shujie DONG ; Li YANG ; Chen CHEN ; Xianwei KONG ; Zheng CAI ; Yawei DU ; Fang LIU ; Jinping ZHU ; Hua JIANG ; Jing HUANG ; Xianhua ZHANG ; Jian WEN ; Xue LI ; Tao HAN ; Hongying GUO ; Jing CUI ; Yuan SHUAI ; Jing LI ; Yingying YAN ; Wei LIU ; Huibo LI ; Yiheng YANG ; Zijian LI ; Rongsheng ZHAO
China Pharmacy 2020;31(5):513-517
OBJECTIVE: To provide reference for improving emergency capacity of the hospital pharmacy department in response to the novel coronavirus pneumonia (COVID-19) epidemic. METHODS :According to the related regulations and requirements of Law of the People ’s Republic of China on the Prevention and Control of Infectious Diseases ,combined with the situation of COVID- 19 epidemic prevention and control ,and management experience of relevant hospitals ,on the basis of in-depth analysis of drug supply and quality assurance ,drug dispensing management ,provision of clinical pharmaceutical services and other related material support of hospital pharmacy department,integrated emergency management model was constructed for COVID- 19 epidemic prevention and control ,and the precautions and response measures of each link were sorted out. RESULTS :Integruted emergency management mode for COVID-19 epidemic prevention and control in hospital pharmacy department included but was not limited to human resource management,drug and disinfection products supply management (mainly including key treatment drugs and disinfection product list formulation,control,inventory increase ,etc.);drug dispensing management (mainly including prescription ,pharmacy window , planning quantitative reserve , drug return , etc.);clinical pharmaceutical care management (mainly including providing pharmaceutical information support ,online pharmaceutical service ,monitoring drug safety ,etc.);personnel protection and disinfection (mainly including personnel protection ,environment and window ,equipment and container ,paper prescription disinfection,etc.);special management of donated drugs ;prevention and control knowledge training ;pharmaceutical education and scientific research management ,etc. CONCLUSIONS :The integrated emergency management model for epidemic prevention and control is helpful for hospital pharmacy to manage public health emergencies. During the outbreak of COVID- 19,hospital pharmacy department should start integrated emergency management mode for epidemic prevention and control ,strengthen the risk control of each link ,and play a good role in the key functional departments in the special period.
9.Principles for the rational use of national key monitoring drugs (the second batch)
Yuan BIAN ; Min CHEN ; Shan DU ; Wenyuan LI ; Lizhu HAN ; Qinan YIN ; Xiaojiao CUI ; Xuefei HUANG ; Zhujun CHEN ; Yang LEI ; Yingying HOU ; Xiaoqing YI ; Yueyuan WANG ; Xi ZHENG ; Xinxia LIU ; Ziyan LYU ; Yue WU ; Lian LI ; Xingyue ZHENG ; Liuyun WU ; Junfeng YAN ; Rongsheng TONG
China Pharmacy 2023;34(20):2433-2453
In order to strengthen the supervision of the use of drugs in hospitals,the Sichuan Academy of Medical Sciences· Sichuan Provincial People’s Hospital took the lead in compiling the Principles for the Rational Use of National Key Monitoring Drugs (the Second Batch) with a number of experts from multiple medical units in accordance with the Second Batch of National Key Monitoring Rational Drug Use List (hereinafter referred to as “the List”) issued by the National Health Commission. According to the method of the WHO Guidelines Development Manual, the writing team used the Delphi method to unify expert opinions by reading and summarizing the domestic and foreign literature evidence of related drugs, and applied the evaluation, formulation and evaluation method of recommendation grading (GRADE) to evaluate the quality of evidence formed, focusing on more than 30 drugs in the List about the evaluation of off-label indications of drugs, key points of rational drug use and key points of pharmaceutical monitoring. It aims to promote the scientific standardization and effective management of clinical medication, further improve the quality of medical services, reduce the risk of adverse drug reactions and drug abuse, promote rational drug use, and improve public health.